Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland

A Retrospective Observational Study to Evaluate the Clinical Outcomes and Routine Management of Patients With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland

The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting

Inclusion Criteria:

• Diagnosis of CLL documented within medical records
• Individuals who have received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation at the time of starting idelalisib treatment
• Idelalisib and rituximab initiated on or before 31 December 2017

Exclusion Criteria:

• Individuals who received idelalisib as part of an interventional clinical trial
• Individuals who received idelalisib for other indications including follicular lymphoma (FL)
• Individuals who previously received idelalisib in combination with ofatumumab
• Use of idelalisib which is not in accordance with its marketing authorisation at the time of starting idelalisib treatment